Hims & Hers Health Shares Skyrocket on Novo Nordisk Deal, but Is the Stock Still a Buy?

Hims & Hers reached an agreement with Novo Nordisk to sell Ozempic injections and Wegovy pills and will drop the related lawsuit, removing a major overhang. Revenue climbed 28% last quarter and the stock trades at under 20x forward P/E for 2026 and below 15x for 2027, leaving valuation still attractive. The deal should drive revenue growth but at lower gross margins, and the company will limit advertising of compounded semaglutide products. Given the prior volatile relationship with Novo, investors are advised to limit position sizes, though sustained partnership could provide further upside.

Analysis

This deal is best viewed as a platform-derisking event rather than a pure margin win: HIMS converts a legal/strategic overhang into an ongoing distribution relationship that should accelerate top-line visibility within 2–4 quarters while ceding a material share of per-prescription gross margin to the brand owner. Expect the contribution to consolidated revenue to be front-loaded via incremental Rx volume and patient acquisition efficiency (faster monetization of existing traffic), plausibly adding a mid-single-digit percentage to next‑12‑month revenues if rollout executes across major markets.

On margins and cash flow, branded product distribution will compress gross margins versus HIMS’ prior compounding mix — our baseline is roughly 700–1,200 bps of gross‑margin erosion on branded semaglutide revenue, translating into a ~200–400 bps headwind to consolidated EBITDA margin at scale. That said, incremental contribution margin still looks positive: branded volumes convert existing marketing spend and reduce marginal CAC, so free cash flow per incremental dollar of revenue should remain accretive once fixed digital marketing and customer service leverage kicks in over 4–8 quarters.

Key tail risks are governance/termination clauses and regulatory escalation. Contracts with a dominant supplier typically include clawbacks, price resets, and short-notice termination triggers — any of which could unwind the revenue lift within 30–180 days; concurrently, an accelerated FDA enforcement playbook against compounding could raise legal/compliance costs and push HIMS to either overcomply (lost revenue) or re-risk the relationship. Monitor quarterly disclosures for rebates, return provisions, and any indemnity language that would cap economics.

Second‑order winners include commerce/logistics partners (cold‑chain fulfillment) and telehealth rivals that lack first‑party Rx fulfillment — they face increased competitive pressure on pricing and patient retention. Contrarian upside is underappreciated: if HIMS uses the Novo arrangement as a template it can become a preferred branded‑drug aggregator, unlocking multiple branded partnerships over 12–36 months and re‑rating the multiple from a consumer-subscription to a high-frequency prescription distribution multiple.

Key Decisions for Investors

• Initiate a tactical long position in HIMS (1–2% portfolio weight) with a 12–18 month horizon; buy equity and hedge downside by purchasing 3–6 month puts ~10% OTM to cap near‑term regulatory/termination tail risk. Rationale: asymmetric upside from platform derisking; cost of put insurance is acceptable versus outright selloff risk.
• If implied volatility for HIMS 12‑18 month options is below its 12‑month historical median, implement a defined‑risk call spread (buy longer‑dated call, sell higher strike) to capture re‑rating while limiting premium outlay. Target payoff: 2x+ return if branded Rx penetration reaches low‑double digits of revenue within 12 months.
• Small event pair: go long HIMS / short NVO (equal dollar, 6–12 month horizon) as a hedgeable bet that HIMS captures outsized distribution economics while Novo shoulders pricing/volume normalization risk. Keep pair size <0.5% portfolio and re-evaluate on any contract disclosure or co-marketing spend data.
• Wait‑and‑watch sentinel trade: if quarterly disclosures show branded semaglutide contribution >5% of revenue or company reports contract terms without onerous return/rebate mechanics, increase HIMS exposure to 3–4% of portfolio within 30 days; conversely, if indemnities/repricing clauses are disclosed, reduce exposure to zero and flip to short on deterioration signals.